Hua Medicine (Shanghai) Ltd. (2552) Earnings Call Transcripts

Hua Medicine (Shanghai) Ltd.'s Latest Earnings Call - March 27, 2026

Hua Medicine reported significant growth in Q4 2025, with a 93% YoY increase in revenue, reaching nearly RMB 500 million. The company achieved profitability, driven by a 91% increase in sales volume and reduced distribution costs. Management maintained guidance for RMB 1 billion in sales by 2027, supported by patent extensions and stable NRDL pricing. The expansion of their glucokinase activator program into new therapeutic areas and the successful commercialization of dorzagliatin in Hong Kong were key highlights.

Reported metrics

Guidance from management

Management maintained guidance for RMB 1 billion in sales by 2027, supported by patent extensions and stable NRDL pricing.

What management said

Yes. I thank everyone to join Pharm Medicine '25 annual report. And then we will reach out in the future and then talk to you more about our adventure and then the future success in the drug discovery and in the commercialization. Thanks.

What analysts pressed on

Analysts questioned the sustainability of the rapid revenue growth and the potential challenges in scaling operations. Concerns were also raised about the competitive landscape with the entry of generic drugs.

Main topics on the call

• Revenue Growth — Hua Medicine achieved a 93% increase in revenue, driven by a 91% increase in sales volume to 4 million packs in Mainland China. This growth was supported by the establishment of an in-house sales team and reduced distrib...
• Patent Extensions — The company secured a 5-year extension on its dorzagliatin patent, ensuring market exclusivity in China until 2034, with formulation patents extending to 2038. This provides a strong competitive advantage.
• Market Expansion — Dorzagliatin was registered in Hong Kong, and the company is developing commercial capabilities in the Greater Bay Area, targeting Southeast Asia's 100 million diabetes patients.
• Clinical Trials and Efficacy — Hua Medicine reported positive results from real-world studies and investigator-initiated trials, demonstrating significant A1c reduction and improved glucose homeostasis in type 2 diabetes patients.

Read the full Hua Medicine (Shanghai) Ltd. transcript (March 27, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 11 Hua Medicine (Shanghai) Ltd. earnings call transcripts on record, spanning March 17, 2020 to August 21, 2026. Based on this history, Hua Medicine (Shanghai) Ltd. reports annually. The most recent call on file is dated August 21, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

2552

Exchange

SEHK

Country

HK

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

11

First call

March 17, 2020

Most recent

August 21, 2026

Reporting cadence

annually